HBM contact: Dr Priyanka Belawat
Company status: private
Predictive Precision Proteomics, AP3, is a proprietary, streamlined approach to
develop patient selection tumor biopsy tests, called OncoSignature® tests.
Company’s lead molecule
ACR-368 is a
potent, selective inhibitor of CHK1 and CHK2 which has shown deep durable
single agent activity, including complete responses, in a proportion of
patients across several Phase 2 studies of platinum-resistant ovarian cancer
and in squamous cell cancers, including anal cancer for which FDA has granted
orphan drug designation.